Clinical function of estrogen receptors in endometrial cancer;Recettori di estrogeni nel carcinoma endometriale: Significato fisiopatologico e clinico

Minerva Ginecologica

Volumn 63, Issue 6, 2011, Pages 495-504

  Caringella, A M ^a   Di Naro, E ^a   Loverro, G ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Endometrial neoplasms; Estrogens; Receptors, estrogen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RELATED RECEPTOR ALPHA; ESTROGEN RECEPTOR;

BINDING SITE; ENDOMETRIUM CARCINOMA; ESTROGEN RESPONSIVE ELEMENT; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; PHYSIOLOGY;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RECEPTORS, ESTROGEN;

EID: 84055217949     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS 707.
2. World Health Organization, International Agency for Research on Cancer. World Cancer Report. Lyon, France: IARC Press; 2003.
3. Amant F, Moerman P, Neven P, Timmerman D, Van LE, Vergote I. Endometrial cancer. Lancet 2005;366:491-505. (Pubitemid 41111699)
4. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-20. (Pubitemid 14073467)
5. Rose PG. Endometrial carcinoma. N Eng J Med 1996;335.640-9.
6. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10. (Pubitemid 27033972)
7. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985;313:969-72. (Pubitemid 15250215)
8. Beral V, Bull D, Reeves G. Endometrial cancer and hormonereplacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
9. Hale GE, Hughes CL, Cline JM. Endometrial cancer: hormonal factors, the perimenopausal "window of risk" and isoflavones. J Clin Endocrinol Metab 2002;87:3-15. (Pubitemid 34084662)
10. Rieck G, Fiander A. The effect of lifestyle factors on gynaecological cancer. Best Pract Res Clin Obstet Gynaecol 2006;20:227-51. (Pubitemid 43380598)
11. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421-30. (Pubitemid 32049639)
12. Gates EJ, Hirschfield L, Matthews RP, Yap OW. Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc 2006;98:1814-22. (Pubitemid 44885538)
13. Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000;11:185-92. (Pubitemid 30088399)
14. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
15. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-2.
16. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007;106:325-33. (Pubitemid 47087930)
17. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002;296:1642-4. (Pubitemid 34579150)
18. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 2006;6:360-8.
19. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7. (Pubitemid 13194678)
20. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:1467-70. (Pubitemid 23056062)
21. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008;199:543.e1-7.
22. Geisinger KR, Homesley HD, Morgan TM, Kute TE, Marshall RB. Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 1986;58:1518-25 (Pubitemid 16016838)
23. Judd HL, Davidson BJ, Frumar AM, Shamonki IM, Lagasse LD, Ballon SC. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1980;136:859-71. (Pubitemid 10112650)
24. Hecht JL, Mutter GL. Molecular and pathologic aspects ofendometrial carcinogenesis. J Clin Oncol 2006;24:4783-91 (Pubitemid 46630943)
25. Bulun SE, Economos K, Miller D, Simpson ER: CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab 1994;79:1831-4.
26. Utsunomiya H, Suzuki T, Kaneko C, Takeyama J, Nakamura J, Kimura K et al. The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. J Clin Endocrinol Metab 2001;86:3436-43. (Pubitemid 32673518)
27. Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I et al. Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer EpidemiolBiomarkers Prev 2009;18:242-7.
28. Berstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003;129:245-9. (Pubitemid 36713801)
29. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K et al. 17β-Hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006;248:136-40.
30. Miller WR, Hawkins RA, Forrest AP. Significance of aromatase activity in human breast cancer. Cancer Res 1982;42:3365-8.
31. Tseng L, Mazella J, Mann WJ, Chumas J. Estrogen synthesis in normal and malignant human endometrium. J Clin Endocrinol Metab 1982;55:1029-31. (Pubitemid 13054375)
32. Yamaki J, Yamamoto T, Okada H. Aromatization ofandrostenedione by normal and neoplastic endometrium ofthe litems. J Steroid Biochem 1985;22:63-6. (Pubitemid 15130259)
33. Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T et al. Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Res 2005;65:657-63.
34. Singh A, Purohit A, Wang DY, Duncan LJ, Ghilchik MW, Reed MJ. IL-6sR: release from MCF-7 breast cancer cells and role in regulating peripheral oestrogen synthesis. J Endocrinol 1995;147:R9-12.
35. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation ofpro moter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42. (Pubitemid 26423150)
36. Ito K, Utsunomiya H, Yaegashi N, Sasano H. Biological roles ofestr ogen and progesterone in human endometrial carcinoma - new developments in potential endocrine therapy for endometrial cancer. Endocr J 2007;54:667-79. (Pubitemid 351377743)
37. Puranen T, Poutanen M, Ghosh D, Vihko P, Vihko R. Characterization ofstmctural and functional properties ofhuman 17β-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis. Mol Endocrinol 1997;11:77-86. (Pubitemid 27021256)
38. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S. Expression cloning and characterization ofhuman 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J Biol Chem 1993; 268:12964-9. (Pubitemid 23182471)
39. Husen B, Psonka N, Jacob-Meisel M, Keil C, Rune GM. Differential expression of 17β-hydroxysteroid dehydrogenases types 2 and 4 in human endometrial epithelial cell lines. J Mol Endocrinol 2000;24:135-44. (Pubitemid 30117667)
40. Utsunomiya H, Suzuki T, Kaneko C, Takeyama J, Nakamura J, Kimura K et al. The analyses of17 β-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. J Clin Endocrinol Metab 2001,86:3436-43. (Pubitemid 32673518)
41. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H. 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 2000;82:518-23. (Pubitemid 30085183)
42. Takahashi-Shiga N, Utsunomiya H, Miki Y, Nagase S, Kobayashi R, Matsumoto M et al. Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions. Clin Cancer Res 2009;15:6028-34.
43. Collins F, MacPherson F, Brown P, Bombail V, Williams A, Anderson R et al. Expression of estrogen receptors, ERα, ERβ, and ERβ variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of Erα. BMC Cancer 2009;9:330.
44. Critchley HO, Brenner RM, Henderson TA, Williams K, Nayak NR, Slayden OD et al. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab 2001;86:1370-8. (Pubitemid 32323030)
45. Witek A, Paul-Samojedny M, Stojko R, Seifert B, Mazurek U. Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma. Gynecol Oncol 2007;106:407-12 (Pubitemid 47087942)
46. Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 2006;103:13162-7. (Pubitemid 44338933)
47. Savouret JF, Bailly A, Misrahi M, Rauch C, Redeuilh G, Chauchereau A et al. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. Embo J 1991;10:1875-83. (Pubitemid 21905656)
48. Kauppila AJ, Isotalo HE, Kivinen ST, Vihko RK. Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 1986;46:5380-4. (Pubitemid 16008319)
49. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998;69:220-5. (Pubitemid 28289963)
50. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142:4120-30. (Pubitemid 32802685)
51. Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004;10:2421-8. (Pubitemid 38445702)
52. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-35.
53. Davies MP, O'Neill PA, Innes H, Sibson DR, Prime W, Holcombe C et al. Correlation of mRNA for oestrogen receptor beta splice variants ER{beta}1, ER{beta}2/ER{beta}cx and ER{beta}5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol 2004;33:773-82. (Pubitemid 40057569)
54. Utsunomiya H, Suzuki T, Harada N, Ito K, Matsuzaki S, Konno R et al. Analysis of estrogen receptor alpha and beta in endometrial carcinomas: correlation with ER beta and clinicopathologic findings in 45 cases. Int J Gynecol Pathol 2000;19:335-41.
55. Skrzypczak M, Bieche I, Szymczak S, Tozlu S, Lewandowski S, Girault I et al. Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium. Int J Cancer 2004;110:783-7. (Pubitemid 38758502)
56. Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Rajwanshi A, Majumdar S. Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer 2007;17:905-13. (Pubitemid 47063317)
57. Scobie GA, Macpherson S, Millar MR, Groome NP, Romana PG et al. Human oestrogen receptors: differential expression of ER alpha and beta and the identification of ER beta variants. Steroids 2002;67:985-92. (Pubitemid 35175466)
58. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997;277:1508-10. (Pubitemid 27449239)
59. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52. (Pubitemid 24059587)
60. Gielen SC, Kuhne LC, Ewing PC, Blok LJ, Burger CW. Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr Relat Cancer 2005;12:1037-49. (Pubitemid 41815795)
61. Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the utems. Endocrinology 2003;144:3159-66. (Pubitemid 36819918)
62. Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol 2005;98:383-9. (Pubitemid 41169148)
63. Bulun SE, Fang Z, Imir G, Gurates B, Tamura M, Yilmaz B, et al. Aromatase and endometriosis. Semin Reprod Med 2004;22:45-50. (Pubitemid 38524583)
64. Brueggemeier RW, Su B, Sugimoto Y, Diaz-Cruz ES, Davis DD. Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol 2007;106:16-23. (Pubitemid 47362646)
65. Tamura M, Deb S, Sebastian S, Okamura K, Bulun SE. Estrogen upregulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 2004;81:1351-6. (Pubitemid 38609321)
66. Punyadeera C, Dunselman G, Marbaix E, Kamps R, Galant C, Nap A et al. Triphasic pattern in the ex vivo response of human proliferative phase endometrium to oestrogens. J Steroid Biochem Mol Biol 2004;92:175-85. (Pubitemid 39535857)
67. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 2001;85:1023-31. (Pubitemid 33016005)
68. Uotila PJ, Erkkola RU, Klemi PJ. The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann Med 2002;34:428-33. (Pubitemid 36026774)
69. Attar E, Tokunaga H, Imir G, Yilmaz MB, Redwine D, Putman M et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab 2009;94:623-31.
70. Fujimoto J, Nakagawa Y, Toyoki H, Sakaguchi H, Sato E, Tamaya T. Estrogen related receptor expression in placenta throughout gestation. J Steroid Biochem Mol Biol 2005;94:67-9. (Pubitemid 40614519)
71. Fujimoto J, Syed SM, Jahan I, Sato E, Sakaguchi H, Tamaya T. Clinical implications of estrogen-related receptor (ERR) expression in ovarian cancers. J Steroid Biochem Mol Biol 2007;104:301-4. (Pubitemid 46891819)
72. Moggs JG, Orphanides G. Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep 2001;2:775-81. (Pubitemid 32982744)
73. Meyer ME, Gronemeyer H, Turcotte B, Bocquel MT, Tasset D, Chambon P. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 1989;57:433-42. (Pubitemid 19126276)
74. Suzuki YM, Moriya T, Shimada N, Ishida T, Hayakawa H, Ohuchi N et al. Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor, Cancer Res 2004,64:4670-6. (Pubitemid 38856942)
75. Vergote I, Kjørstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64:1011-6. (Pubitemid 19208849)
76. Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001;19:4048-53. (Pubitemid 32976691)
77. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007;106:325-33. (Pubitemid 47087930)
78. Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W et al. The activity oflet rozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute ofCanada Clinical Trials Group. Int J Gynecol Cancer 2004;14:650-8. (Pubitemid 39062922)
79. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial ofana strozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000;78:212-6. (Pubitemid 30650356)